Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO)
Tang Capital Management, LLC and related entities have disclosed a beneficial ownership of 1,160,000 Ordinary Shares in Crescent Biopharma (CBIO), representing 4.21% of the company's outstanding shares. This information was reported in an amended Schedule 13G/A SEC filing, indicating shared voting and dispositive power among the Tang Capital entities and Kevin Tang. The filing specifies that the percentage is calculated based on 27,571,935 Ordinary Shares outstanding as of April 7, 2026.
FEB 23·Yahoo Finance Singapore▲
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma, Inc. (Nasdaq: CBIO) announced it will present at two investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference and the Leerink Partners 2026 Global Healthcare Conference. The company, a clinical-stage biotechnology firm focused on cancer therapies, will provide live webcasts and replays of these presentations on its investor relations website.
JAN 15·TipRanks▲
Crescent Biopharma Advances CR-001 Cancer Trial Into First-in-Human Stage
Crescent Biopharma, Inc. (CBIO) has announced the advancement of its CR-001 cancer trial into the first-in-human stage with a Phase 1/2 study. The trial aims to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of CR-001 in adults with locally advanced or metastatic solid tumors. While the study is currently in the "Not Yet Recruiting" phase, this marks a significant value inflection point for the biotech firm, potentially influencing future capital raises or partnerships.
